Us Bancorp \De\ Bei Gene, Ltd. Transaction History
Us Bancorp \De\
- $74.1 Billion
- Q1 2025
A detailed history of Us Bancorp \De\ transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Us Bancorp \De\ holds 1,084 shares of BGNE stock, worth $245,753. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,084
Previous 741
46.29%
Holding current value
$245,753
Previous $136,000
80.15%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding BGNE
# of Institutions
267Shares Held
42.3MCall Options Held
135KPut Options Held
111K-
Baker Bros. Advisors LP New York, NY9.53MShares$2.16 Billion19.52% of portfolio
-
Capital International Investors Los Angeles, CA6.11MShares$1.39 Billion0.22% of portfolio
-
Primecap Management CO Pasadena, CA5.06MShares$1.15 Billion0.97% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E93.8MShares$862 Million26.88% of portfolio
-
Baillie Gifford & CO3.63MShares$823 Million0.74% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...